Thyroid Nodules: Can Immune Cell Analysis Replace Genetic Testing?
"Emerging research suggests that analyzing immune cell infiltration in thyroid nodules could offer a simpler, more reliable diagnostic approach than current molecular tests."
Thyroid nodules are common, and determining whether they are benign or malignant is a frequent clinical challenge. Current diagnostic methods often rely on fine needle aspiration (FNA) followed by cytological analysis. However, when FNA results are indeterminate, molecular testing is often employed to further assess the risk of malignancy.
While molecular tests have become increasingly sophisticated, they can sometimes yield ambiguous or conflicting results. This has led researchers to explore alternative approaches, including the analysis of immune cells within the nodule microenvironment. The rationale is that the presence and distribution of specific immune cell types, such as dendritic cells (DCs) and regulatory T cells (Tregs), may reflect the underlying nature of the nodule.
Two recent studies presented in this article explore the potential of using immune cell markers, specifically CD1a for DCs and FoxP3 for Tregs, to predict malignancy in thyroid nodules. By examining the presence and distribution of these immune cells, researchers aim to refine diagnostic accuracy and potentially reduce the reliance on complex molecular testing.
Immune Profiles in Thyroid Nodules
The tumor immune microenvironment is established as relevant to thyroid cancer, but the Frontiers study published on January 28, 2025, noted that limited data exist on differences in immune-cell presence between thyroid adenomas and carcinomas. A 2020 computational study described itself as the first evaluation of tumor-infiltrating immune cells across a comprehensive cohort of thyroid-lesion subtypes. Its findings emphasized that thyroid nodules have varied immune compositions. Immunocytochemistry and molecular testing are being used as ancillary techniques to improve risk-of-malignancy assessment and management.
Current Diagnostic Pathway
Thyroid nodules can be detected by palpation in about 5% of cases and by ultrasound in about 70% of cases, according to the cited 2025 review. Because only 5–10% of evaluated thyroid nodules are malignant, excluding cancer is a central task of assessment. Molecular tests are used particularly when cytology is indeterminate, but systematic reviews have identified bias and methodological limitations in studies validating these tests. A benign molecular result does not eliminate the likelihood of thyroidectomy in patients with compressive symptoms, hyperthyroidism, nodules larger than 4 cm, or nodule growth during follow-up.
Evolution of Nodule Evaluation
Thyroid-nodule evaluation has progressively incorporated clinical assessment, imaging, cytology, immunocytochemistry, and molecular approaches. This progression reflects the difficulty of distinguishing benign from malignant nodules using a single method. Immune-cell analysis represents a newer research direction that may complement, rather than immediately replace, established diagnostic tools. Its historical role and long-term clinical position remain under development.
Immune Cell Infiltration: A Novel Diagnostic Marker?
One study investigated the immune cell composition of both cancerous and non-cancerous thyroid tissue samples. The researchers found that malignant thyroid tissues, specifically papillary thyroid carcinoma (PTC), follicular variant PTC (FVPTC), and follicular carcinoma (FC), exhibited significantly higher levels of DC infiltration compared to benign thyroid tissues. Moreover, the combined presence of both DCs and Tregs was even more strongly associated with malignancy.
- High Specificity: Immune cell markers show strong ability to rule out malignancy when absent.
- Improved Accuracy: Combining DC and Treg markers enhances diagnostic precision.
- Potential for Reduced Molecular Test Usage: Refined risk assessment may decrease reliance on complex tests.
Emerging Immune-Repertoire Research
Recent reviews describe thyroid nodules as widespread and generally associated with positive outcomes, while emphasizing that accurate diagnosis remains important for selecting follow-up or treatment. A study published on March 19, 2025, compared peripheral T-cell receptor and B-cell receptor immune repertoires among patients with early-stage papillary thyroid carcinoma, patients with benign thyroid nodules larger than 4 cm, and healthy controls. This design directly examines whether immune-repertoire patterns can distinguish malignant nodules from clinically relevant benign nodules. Comprehensive reviews continue to place such research within broader strategies for thyroid-nodule prevalence assessment, risk stratification, and management.
Persistent Diagnostic Uncertainty
The prevalence of thyroid nodules has increased in recent decades, largely because cervical imaging detects incidentalomas and, in some cases, screening is performed in people without thyroid-disease risk. Fine-needle aspiration provides an economical and accurate diagnosis of nodular thyroid disease, but the cited 2025 review states that cytology remains limited, particularly for indeterminate nodules. These limitations create the setting in which molecular and immune-based tests are considered, but they also show why a new marker cannot be assumed to resolve diagnostic uncertainty on its own. Any proposed replacement for genetic testing would therefore need to address the unresolved limitations of cytologic evaluation.
Immune and Genetic Evidence
Immune-cell analysis and genetic testing examine different biological features of a thyroid nodule. Genetic methods may provide molecular information, while immune approaches assess cellular composition or immune-repertoire patterns. The available evidence suggests that immune analysis is best viewed as a potential complement until comparative studies establish whether it can match or exceed genetic testing for clinically important decisions. A definitive replacement claim would require consistent validation across diverse thyroid-nodule populations.
Refining Diagnostic Strategies for Thyroid Nodules
The findings presented in this article highlight the evolving landscape of thyroid nodule diagnosis. While molecular testing has undoubtedly improved our ability to identify malignant nodules, it is not a perfect solution. The analysis of immune cell infiltration offers a complementary approach that may enhance diagnostic accuracy and reduce the need for unnecessary surgeries.
A Complementary Role
The current evidence supports immune analysis as a promising addition to thyroid-nodule evaluation rather than an established substitute for genetic testing. Immune profiles may add information about the biological environment surrounding a nodule, while cytology and molecular testing remain part of current diagnostic practice. The most defensible interpretation is that immune markers could refine risk assessment when existing findings are inconclusive. Whether they can replace genetic testing remains an open research question.
Toward Integrated Diagnostics
Future research is likely to evaluate immune-cell measurements alongside cytology, imaging, and molecular findings. Progress will depend on determining whether immune signatures reliably distinguish benign and malignant nodules and whether they improve decisions beyond existing tests. Studies will also need to clarify performance in clinically difficult groups, including large benign nodules and indeterminate lesions. Until that evidence is available, immune analysis should be considered an emerging investigational approach.
The Tumor Immune Landscape
Thyroid tumor cells can evade immune destruction by promoting an immunosuppressive microenvironment, according to the cited reviews. This means that immune-cell patterns may reflect both the host response and mechanisms that support tumor persistence. Using NanoString Technology, researchers divided thyroid tumors into two main clusters based on expression of immune-related genes. These findings illustrate both the potential value and the complexity of interpreting immune signals in thyroid cancer.
Reducing Unnecessary Intervention
New studies are exploring immune-cell markers to improve the accuracy of thyroid-nodule diagnosis, potentially reducing unnecessary surgeries and refining molecular-testing strategies. A 2024 study developed MeIS, a diagnostic tool using 15 DNA-methylation markers derived from genes related to immune responses. The study reported that combining DNA methylation with immune signatures may improve diagnostic accuracy. These approaches could affect patients by helping clinicians make more informed decisions about surgery and follow-up, although further validation is needed.
Moreover, integrating immune cell data with molecular testing results could provide a more comprehensive assessment of malignancy risk. For example, a nodule with indeterminate cytology and borderline molecular test results could be further evaluated based on its immune cell profile. This integrated approach could lead to more personalized and effective management strategies for patients with thyroid nodules.
As research in this area continues to advance, it is likely that immune cell analysis will play an increasingly important role in the diagnosis and management of thyroid nodules. By combining traditional cytological methods with emerging molecular and immunological techniques, clinicians can strive to provide the most accurate and personalized care for their patients.